




- (51) **International Patent Classification:**
C07K 14/47 (2006.01) *A61K 38/16* (2006.01)
- (21) **International Application Number:**
PCT/US2022/029628
- (22) **International Filing Date:**
17 May 2022 (17.05.2022)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
63/189,507 17 May 2021 (17.05.2021) US
- (71) **Applicants:** **EMORY UNIVERSITY** [US/US]; 1599 Clifton Road NE, 4th Floor, Office of Technology Transfer, Atlanta, 30322 (US). **CAMBIUM ONCOLOGY LLC** [US/US]; 890 Los Angeles Ave., N.E., Atlanta, Georgia 30306-3602 (US).
- (72) **Inventor; and**
- (71) **Applicant:** **RAVINDRANATHAN, Sruthi** [—/US]; c/o Emory University Office of Technology Transfer, 1599 Clifton Road NE, 4th Floor, Atlanta, Georgia 30322 (US).
- (72) **Inventors:** **WALLER, Edmund, K.**; B519 Winship Cancer Institute, Atlanta, Georgia 30322 (US). **LI, Jian-Ming**; 3050 Wembley Forest Ct., Atlanta, Georgia 30340 (US). **FNU, Passang, Tensing**; c/o Emory University Office of Technology Transfer, 1599 Clifton Road NE, 4th Floor, Atlanta, Georgia 30322 (US). **MAJUMDAR, Anish, Sen**; c/o Emory University Office of Technology Transfer, 1599 Clifton Road NE, 4th Floor, Atlanta, Georgia 30322 (US).
- (74) **Agent:** **FENG, Yanjun** et al.; Meunier Carlin & Curfman LLC, 999 Peachtree Street, NE, Suite 1300, Atlanta, Georgia 30309 (US).
- (81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,

(54) **Title:** VASOACTIVE INTESTINAL PEPTIDE (VIP) RECEPTOR ANTAGONISTS



(57) **Abstract:** Disclosed are VIP-R antagonists for uses in managing the treatment or prevention of cancer and viral infections. In certain embodiments, this disclosure relates to chimeric variants of VIP-R antagonists, as peptides disclosed herein, and pharmaceutical composition comprising the same. In certain embodiments, this disclosure contemplates methods of treating subjects with cancer or infection with VIP-R antagonists or stimulating immune cells to target cancer by mixing immune cells in vitro with peptides disclosed herein and further administering an effective amount of stimulated immune cells to a subject in need of cancer treatment.

[Continued on next page]

DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*